ADVM (Adverum Biotechnologies) 3-Year Book Growth Rate : -52.70% (As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Adverum Biotechnologies 3-Year Book Growth Rate?

Adverum Biotechnologies's Book Value per Share for the quarter that ended in Mar. 2025 was $1.27.

During the past 12 months, Adverum Biotechnologies's average Book Value per Share Growth Rate was -85.60% per year. During the past 3 years, the average Book Value per Share Growth Rate was -52.70% per year. During the past 5 years, the average Book Value per Share Growth Rate was -37.50% per year. During the past 10 years, the average Book Value per Share Growth Rate was -23.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Adverum Biotechnologies was 5.90% per year. The lowest was -52.70% per year. And the median was -18.70% per year.

Competitive Comparison of Adverum Biotechnologies's 3-Year Book Growth Rate

For the Biotechnology subindustry, Adverum Biotechnologies's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adverum Biotechnologies's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Adverum Biotechnologies's 3-Year Book Growth Rate falls into.

Save Embed

;

Save Embed

;

Adverum Biotechnologies 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Adverum Biotechnologies (NAS:ADVM) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Adverum Biotechnologies 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Adverum Biotechnologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (NAS:ADVM) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

0HA3:UK AVU0:Germany

Address

100 Cardinal Way, Redwood CIty, CA, USA, 94063

Website

https://www.adverum.com

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

Executives

Peter Soparkar	officer: Chief Legal Officer	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Setareh Seyedkazemi	officer: Chief Development Officer	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL DRIVE, REDWOOD CITY CA 94063
Laurent Fischer	director, officer: CEO and Director	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Lupher, Jr. Mark L.	director	C/O ADVERUM BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, MENLO PARK CA 94025
James Paul Scopa	director	601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
C. David Nicholson,	director	103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Linda M Rubinstein	officer: Chief Financial Officer	25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Brigit Riley	officer: Chief Scientific Officer	100 CARDINAL WAY, REDWOOD CITY CA 94063
Richard Beckman	officer: Chief Medical Officer	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Nancy E Pecota	officer: Principal Accounting Officer	ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
John Rakow	officer: SVP, Genl Counsel, Acting CFO	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Rupert D'souza	officer: Chief Financial Officer	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Soo Hong	director	C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY CA 94063
Rabia Gurses Ozden	director	C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210